Home > Cardiology > AHA 2021 > COVID-19 & the Heart > Icosapent ethyl did not reduce the risk of hospitalisation in COVID-19

Icosapent ethyl did not reduce the risk of hospitalisation in COVID-19

Presented By
Dr Rafael Díaz, Estudios Clínicos Latinoamérica, Argentina
Conference
AHA 2021
Trial
PREPARE IT-2
Icosapent ethyl did not significantly influence hospital outcomes in an outpatient COVID-19 population. However, all clinical outcome measures trended towards a benefit of icosapent ethyl in the PREPARE-IT 2 trial. The agent was well tolerated and did not inflict notable safety issues [1]. Icosapent ethyl is an oral form of eicosapentaenoic acid (EPA) that has been associated with a risk reduction of cardiovascular events in the phase 3 REDUCE-IT trial (NCT01492361 [2]. Moreover, the phase 2 Cardiolink-9 trial (NCT04412018) displayed symptom-reducing and inflammation-reducing qualities of icosapent ethyl in patients with COVID-19 [3]. The current PREPARE IT-2 trial, presented by Dr Rafael Díaz (Estudios Clínicos Latinoamérica, Argentina), investigated the efficacy and safety of icosapent ethyl in non-hospitalised patients with COVID-1...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on